ReviewTherapeutic advances in chronic disease2019
TNF-α inhibitors in the treatment of hidradenitis suppurativa.
Review in Therapeutic advances in chronic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa.The British journal of dermatology · 2025Pooled it
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment.Orphanet journal of rare diseases · 2025Pooled it
- Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.International journal of molecular sciences · 2020Pooled it
- Probable Association Between Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Case Report.Cureus · 2026Article
- Targeting Neutrophil Function as Therapy for Hidradenitis Suppurativa.International journal of molecular sciences · 2026Review
- Molecular cytokine-dependent mechanisms of periodontitis pathogenesis and the potential for pharmacological IL-1 modulation in disease treatment.Frontiers in dental medicine · 2026Review
- Combination of mechanical debridement and interleukin 12 or interleukin 23 therapy for refractory facial pyoderma gangrenosum with NOD2 mutation.JAAD case reports · 2025Article
- Shedding Light on Hidradenitis Suppurativa Activity: A Pilot Study to Evaluate the Potential of [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Unravelling the Link Between Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Literature Review.Biomedicines · 2025Review
- Hermansky-Pudlak Syndrome Complicated by Crohn's Disease and Hidradenitis Suppurativa: A Case of Multisystem Immune Dysregulation.ACG case reports journal · 2025Article
- Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II.Clinical, cosmetic and investigational dermatology · 2025Article
- Identification and Validation of Hub Genes in Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2025Article
- Pediatric-onset hidradenitis suppurativa: a case series of 42 patients.Postepy dermatologii i alergologii · 2024Article
- Article
- Infliximab inhibits TNF-α-dependent activation of the NLRP3/IL-1β pathway in acne inversa.Heliyon · 2024Article
- New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.The Journal of dermatology · 2024Review
- Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment.Biomedicines · 2024Review
- Single-cell mass cytometry in immunological skin diseases.Frontiers in immunology · 2024Review
- Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing.JID innovations : skin science from molecules to population health · 2024Article
- The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.Therapeutic advances in chronic disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a complex disease with a dramatic impact on the quality of life of patients that it afflicts. Despite this, there are few treatment options offering long-term relief. The exact pathophysiology of HS is unclear, although the current theory involves follicular obstruction, rupture, and subsequent inflammation leading to fistula and abscess development in intertriginous skin. Several inflammatory modulators have been implicated in the development of HS, including tumor necrosis factor (TNF)-α as well as interleukin (IL)-1β, IL-10, and IL-17. Initial evidence for the use of TNF-α inhibitors in HS stemmed from recognition that inflammatory bowel disease patients treated with these medications saw a concurrent improvement in their HS symptoms. Early case reports and case series illustrated TNF-α inhibitors' value in the treatment of HS. Later, two phase III clinical trials, PIONEER I and PIONEER II, demonstrated that adalimumab is an efficacious treatment for HS. Infliximab represents another effective HS treatment option with its main advantage being dosing flexibility. In contrast, clinical trials have failed to show evidence for application of etanercept in HS. There is limited data on other TNF-α inhibitors such as certolizumab-pegol and golimumab. This review outlines the history, dosing, response, and adverse effects of TNF-α inhibitors in the treatment of HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.